The pharma leg’s long bet: buying KM Biologics (2018)

A vaccine foothold that is both edge and exposure

Acquiring KM Biologics for $385M (¥43bn) added vaccines and infectious disease to a pharmaceutical arm whose origins lay in the 1946 fermentation pivot — the same food-and-medicine base, carried forward by seventy years. Paired with Medreich, the Indian generics maker taken in 2015, it gave Meiji a global contract-manufacturing base and the beginnings of a fifteen-year run-up to Kostaive, a next-generation replicon vaccine. Read one way, this was the two-legged structure working exactly as designed: steady branded food underwriting a patient, research-heavy push into high-value health science that a pure confectioner could never attempt.

Read another way, it was the structure at its most exposed. Kostaive became Meiji’s boldest claim to differentiated health value, yet in 2024 it drew misinformation-driven public backlash and an inventory write-down that fell straight through to group results. The health-value pivot that is Meiji’s sharpest edge is, concentrated in the drug leg, also its most volatile liability — a small, capital- and reputation-sensitive business whose swings the far larger food side is left to absorb. Whether the KM Biologics bet becomes a genuine third pillar or a recurring drag is the open verdict on Meiji’s two-legged design.